Clinical review of the identification and management of infants born to mothers with thyroid disease - is there a role for routine testing of maternal TRAB in the current practice? [PDF]
, 2015 Lucy Malpas
openalex +1 more source
Explaining Job Polarization: Routine-Biased Technological Change and Offshoring
, 2014 M. Goos, A. Manning, A. Salomons
semanticscholar +1 more source
Molecular Oncology, EarlyView.Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang +3 more
wiley +1 more source
IEEE Transactions on Medical Imaging, 2016 K. Sirinukunwattana +5 more
semanticscholar +1 more source
Tumor mutational burden as a determinant of metastatic dissemination patterns
Molecular Oncology, EarlyView.This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal +4 more
wiley +1 more source
Routine transfer of multiple embryos is no longer necessary to achieve high rates of healthy singleton births per transfer in women up to 42 years old [PDF]
, 2017 M.C. Schiewe +5 more
openalex +1 more source
Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin
Molecular Oncology, EarlyView.Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon +4 more
wiley +1 more source
P6246Utilization and effectiveness of alirocumab and evolocumab in improving lipid profile in routine clinical practice [PDF]
, 2017 Peter A. Noseworthy +2 more
openalex +1 more source
Thrombolytic proteins profiling: High‐throughput activity, selectivity, and resistance assays
FEBS Open Bio, EarlyView.We present optimized biochemical protocols for evaluating thrombolytic proteins, enabling rapid and robust screening of enzymatic activity, inhibition resistance, and fibrin affinity, stimulation, and selectivity. The outcome translates to key clinical indicators such as biological half‐life and bleeding risk. These assays streamline the development of
Martin Toul +3 more
wiley +1 more source